Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found. At week 24, 45% of patients ...

Please provide your email address to receive an email when new articles are posted on . Treatment with guselkumab results in higher enthesitis resolutions rates at week 24, with maintenance of those ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving tofacitinib had fewer enthesitis relapses following initial resolution after 1 or 3 months.

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their ...

Patients with ankylosing spondylitis taking secukinumab saw improvements in enthesitis, and some achieved complete resolution, suggesting the drug could be a viable option for patients intolerant of ...

Around 5% of patients treated with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis experience musculoskeletal (MSK) symptoms, according to the results of a descriptive study. The main ...

Certain new concepts in joint disease are gradually being introduced and treated. One such painful condition is named ‘enthesitis’. Although not exactly a type of ‘arthritis’, enthesitis could be ...

The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA. The Food and Drug ...

In this cross-sectional study, Poggenborg and colleagues evaluated the ability of an emerging imaging technology, "whole-body" MRI (WBMRI), to detect enthesitis in patients with psoriatic arthritis ...

The monoclonal antibody guselkumab (Tremfya), which targets the p19 subunit of interleukin (IL)-23, was effective for treating the enthesitis and dactylitis components of psoriatic arthritis (PsA), ...

The interleukin-23 (IL-23) signalling pathway has previously been linked with spondyloarthritis, but it has been unclear how this cytokine can promote disease pathogenesis. A new research study ...